Valeant CEO J. Michael Pearson and the company's largest shareholder, Bill Ackman, have been trying to propel Allergan's board toward deal negotiations ever since they announced their first unsolicited bid back in April. And now, they're adding a little extra incentive.
written on 02.06.2014